Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors

The method of 1, wherein the method is for treating a human coronavirus infection or a symptom thereof, and wherein said administering comprises:

• (a) determining that the human subject is infected with a coronavirus;
• (b) administering to the human subject at least one initial dose of about 15 mg to about 600 mg of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising about 15 mg to about 600 mg of a compound of Formula (I) or a pharmaceutically acceptable salt thereof;
• and
• (c) administering to the human subject a plurality of subsequent doses of about 15 mg to about 400 mg of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising about 15 mg to about 400 mg of a compound of Formula (I) or a pharmaceutically acceptable salt thereof,
• wherein not more than 600 mg of a compound of Formula (I) is administered per day,
• wherein said subsequent doses are administered once, twice, three, or four times per day, and
• wherein Formula (I) has the following structure:
• wherein R1, R2, and R3 are independently H, (C1-C14) acyl, (C1-C14) alkenylacyl, (C3-C8) cycloalkylacyl, (C1-C14) haloalkylacyl (C1-C8) alkoxyacyl, or (C6-C10) arylacyl.

A composition of matter, comprising:

• (a) packaged dosage formulation comprising an alpha-glucosidase glycoprotein processing inhibitor, in a pharmaceutically acceptable dosage in one or more packages, packets, or containers;
• and instructions for administering the alpha-glucosidase glycoprotein processing inhibitor, to treat or prevent human coronavirus infection;
• or
• (b) a kit comprising, in one or more containers, alpha-glucosidase glycoprotein processing inhibitor;
• and instructions for administering the alpha-glucosidase glycoprotein processing inhibitor to treat or prevent human coronavirus infection.